SCHEMBL4462271

SCHEMBL4462271

CC(=O)c1ccc(C(=O)Nc2ccc(F)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.73
MITF O75030 1/20 0.71
RAB9A P51151 3/20 0.70
NPC1 O15118 2/20 0.70
ATM Q13315 1/20 0.70
NOS1 P29475 1/20 0.65
NOS2 P35228 1/20 0.65
KMT2A Q03164 6/20 0.65
MEN1 O00255 5/20 0.65
POLB P06746 3/20 0.65
TDP1 Q9NUW8 1/20 0.65
SNCA P37840 1/20 0.63
ALDH1A1 P00352 2/20 0.61
MAPT P10636 1/20 0.61
CYP2C9 P11712 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6227123 1.00 PTPN1 (0.73) PTPN1MITFRAB9ANPC1ATM
SCHEMBL6459176 0.90 NPC1 (0.69) RAB9ANPC1ATMKMT2AMEN1
SCHEMBL10684470 0.90 PTPN1 (0.88) PTPN1MITFRAB9ANPC1ATM
SCHEMBL4106292 0.87 ALDH1A1 (0.71) RAB9ANPC1KMT2AMEN1POLB
SCHEMBL14433920 0.86 PTPN1 (0.69) PTPN1MITFRAB9ANPC1ATM
SCHEMBL10192214 0.85 RAB9A (0.81) PTPN1MITFRAB9ANPC1ATM
SCHEMBL3223877 0.85 RAB9A (0.81) PTPN1MITFRAB9ANPC1ATM
SCHEMBL8771885 0.85 KMT2A (0.63) RAB9ANPC1ATMKMT2AMEN1
SCHEMBL8770854 0.85 PTPN1 (0.79) PTPN1MITFRAB9ANPC1ATM
SCHEMBL13986883 0.85 CACNA1B (0.76) RAB9ANPC1ATMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
CN-1795179-A Novel imidazole derivatives, the production thereof, and the use of the same as a medicament SOD CONSEILS RECH APPLIC (FR) 2006-06-28 CN disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 PTPN1 4446/4885MITF 272/4885RAB9A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.